226 related articles for article (PubMed ID: 11924798)
21. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
22. [Genetically engineered mice and its application to bioindustry].
Koda T; Togashi Y; Nishimura T
Hokkaido Igaku Zasshi; 2002 Mar; 77(2):151-6. PubMed ID: 11968850
[TBL] [Abstract][Full Text] [Related]
23. Introduction: Strategies for developing genetically modified mice.
Hofker MH
Methods Mol Biol; 2011; 693():1-10. PubMed ID: 21080271
[TBL] [Abstract][Full Text] [Related]
24. The influence of genetic background on spontaneous and genetically engineered mouse models of complex diseases.
Linder CC
Lab Anim (NY); 2001 May; 30(5):34-9. PubMed ID: 11385732
[TBL] [Abstract][Full Text] [Related]
25. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
[TBL] [Abstract][Full Text] [Related]
26. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.
Cryan JF; Mombereau C
Mol Psychiatry; 2004 Apr; 9(4):326-57. PubMed ID: 14743184
[TBL] [Abstract][Full Text] [Related]
27. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Long GG; Morton D; Peters T; Short B; Skydsgaard M
Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
[TBL] [Abstract][Full Text] [Related]
28. Animal models of neoplastic development.
Pitot HC
Dev Biol (Basel); 2001; 106():53-7; discussion 57-9, 143-60. PubMed ID: 11761267
[TBL] [Abstract][Full Text] [Related]
29. Repair characteristics and differentiation propensity of long-term cultures of epidermal keratinocytes derived from normal and NER-deficient mice.
Backendorf C; de Wit J; van Oosten M; Stout GJ; Mitchell JR; Borgstein AM; van der Horst GT; de Gruijl FR; Brouwer J; Mullenders LH; Hoeijmakers JH
DNA Repair (Amst); 2005 Nov; 4(11):1325-36. PubMed ID: 16182615
[TBL] [Abstract][Full Text] [Related]
30. Transgenic animal models in toxicology: historical perspectives and future outlook.
Boverhof DR; Chamberlain MP; Elcombe CR; Gonzalez FJ; Heflich RH; Hernández LG; Jacobs AC; Jacobson-Kram D; Luijten M; Maggi A; Manjanatha MG; Benthem Jv; Gollapudi BB
Toxicol Sci; 2011 Jun; 121(2):207-33. PubMed ID: 21447610
[TBL] [Abstract][Full Text] [Related]
31. Transgenic animal models that might be useful in identifying unsuspected oncogenic factors in tumour cell substrates.
Sistare FD
Dev Biol (Basel); 2001; 106():123-31; discussion 131-2, 143-60. PubMed ID: 11761226
[TBL] [Abstract][Full Text] [Related]
32. Probing p53 biological functions through the use of genetically engineered mouse models.
Attardi LD; Donehower LA
Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709
[TBL] [Abstract][Full Text] [Related]
33. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
[TBL] [Abstract][Full Text] [Related]
34. Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes.
Melis JP; Wijnhoven SW; Beems RB; Roodbergen M; van den Berg J; Moon H; Friedberg E; van der Horst GT; Hoeijmakers JH; Vijg J; van Steeg H
Cancer Res; 2008 Mar; 68(5):1347-53. PubMed ID: 18316597
[TBL] [Abstract][Full Text] [Related]
35. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice.
Hoogervorst EM; van Oostrom CT; Beems RB; van Benthem J; Gielis S; Vermeulen JP; Wester PW; Vos JG; de Vries A; van Steeg H
Cancer Res; 2004 Aug; 64(15):5118-26. PubMed ID: 15289314
[TBL] [Abstract][Full Text] [Related]
36. Current issues in mouse genome engineering.
Glaser S; Anastassiadis K; Stewart AF
Nat Genet; 2005 Nov; 37(11):1187-93. PubMed ID: 16254565
[TBL] [Abstract][Full Text] [Related]
37. Designing mouse behavioral tasks relevant to autistic-like behaviors.
Crawley JN
Ment Retard Dev Disabil Res Rev; 2004; 10(4):248-58. PubMed ID: 15666335
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
[TBL] [Abstract][Full Text] [Related]
39. The use of genetically modified mice in cancer risk assessment: challenges and limitations.
Eastmond DA; Vulimiri SV; French JE; Sonawane B
Crit Rev Toxicol; 2013 Sep; 43(8):611-31. PubMed ID: 23985072
[TBL] [Abstract][Full Text] [Related]
40. Xeroderma pigmentosum group E and DDB2, a smaller subunit of damage-specific DNA binding protein: proposed classification of xeroderma pigmentosum, Cockayne syndrome, and ultraviolet-sensitive syndrome.
Itoh T
J Dermatol Sci; 2006 Feb; 41(2):87-96. PubMed ID: 16325378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
